Skip to main
LONA

LeonaBio Inc (LONA) Stock Forecast & Price Target

LeonaBio Inc (LONA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LeonaBio is currently enrolling the Ph. 3 ELAINE-3 trial of lasofoxifene + abema vs. fulvestrant + abema in approximately 600 post-CDK4/6 ER+/HER2- breast cancer patients with an ESR1 mutation, a treatment combination that could potentially leapfrog other novel endocrine therapies currently being evaluated as monotherapies. LeonaBio's financials are strong, with over $50 million in cash as of 2Q26, and the company is well-funded to execute the ELAINE-3 trial and pursue other potential drug candidates in its pipeline. Additionally, LeonaBio's focus on developing novel therapies for high unmet medical needs, such as metastatic breast cancer and ALS, positions the company well for potential success in these areas.

Bears say

LeonaBio is currently facing major challenges as their clinical trials for their key drug candidates, lasofoxifene and ATH-1105, have not shown significant promise. Renewed interest in their drugs has not led to an increase in stock value as their most recent data did not meet primary and secondary endpoints. Additionally, a previous program for Alzheimer's failed to meet its primary endpoint, further dampening the potential outlook for the company.

LeonaBio Inc (LONA) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeonaBio Inc (LONA) Forecast

Analysts have given LeonaBio Inc (LONA) a Buy based on their latest research and market trends.

According to 3 analysts, LeonaBio Inc (LONA) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeonaBio Inc (LONA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.